Evotec (NASDAQ:EVO) Shares Gap Down to $7.24

Evotec SE (NASDAQ:EVO)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $7.24, but opened at $7.04. Evotec shares last traded at $7.03, with a volume of 6,390 shares traded.

Analysts Set New Price Targets

A number of equities analysts have weighed in on EVO shares. Royal Bank of Canada raised shares of Evotec from a “sector perform” rating to an “outperform” rating in a research note on Thursday, January 18th. Deutsche Bank Aktiengesellschaft raised shares of Evotec from a “hold” rating to a “buy” rating in a research note on Friday, April 12th.

Evotec Stock Down 0.7 %

The stock’s 50 day moving average price is $7.39 and its 200 day moving average price is $8.76.

Institutional Trading of Evotec

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mubadala Investment Co PJSC bought a new position in shares of Evotec during the fourth quarter valued at approximately $53,931,000. OLD Mission Capital LLC bought a new position in shares of Evotec during the fourth quarter valued at approximately $141,000. Optiver Holding B.V. grew its holdings in shares of Evotec by 643.1% during the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after purchasing an additional 69,936 shares during the last quarter. Finally, Quadrant Capital Group LLC acquired a new position in shares of Evotec during the fourth quarter worth approximately $25,000. 5.81% of the stock is owned by institutional investors.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.